Tenaya Therapeutics (TNYA) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 55.1% versus a loss of 70.3%. Over five years, VYGR leads with a -42.2% price change compared with -97.4% for TNYA. Voyager Therapeutics is the larger company by market cap ($146.0 million vs $122.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNYA | VYGR |
|---|---|---|
| Share price | $0.5442 | $2.37 |
| Market cap | $122.03M | $146.03M |
| 1-day change | +2.02% | -4.05% |
| YTD return | -23.57% | -39.69% |
| 1-year return | -70.26% | -55.11% |
| 5-year return | -97.35% | -42.20% |
| EPS (TTM) | $-0.52 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.35 | $5.55 |
| 52-week low | $0.5211 | $2.33 |
| Distance from 52-week high | -76.84% | -57.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +488.02% | +528.27% |
| Average volume | 2.26M | 573.14K |
| Shares outstanding | 224.23M | 61.62M |
| Employees | 70 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed TNYA by 15.1 percentage points over the past year.
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
TNYA vs VYGR FAQ
Which is bigger, Tenaya Therapeutics or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $146.03M compared with $122.03M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, TNYA or VYGR?
VYGR returned -55.11% over the past 12 months, compared with -70.26% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Tenaya Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.